Skip to main content

Table 2 Anthropometry, lab values and concomitant medication at baseline and week 38, median (range)

From: Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease

  Baseline Week 38
Weight, kg (z score for age)
Crohn’s disease (CD) 44.4 (1.05) 48 (1.26)
Ulcerative colitis (UC) 34.3 (1.36) 44 (1.86)
Height, cm
CD 164.0 (138–172) 164.2 (140–172)
UC 146 (127–155) 148 (130–155.5)
Haemoglobin, g/dl
CD 8.4 (6.9–13.0) 10.5 (7.8–12.3)
UC 10.4 (8.0–12,3) 12.1 (8.0–14.8)
Haematocrit, %
CD 26.2 (22.9–40.1) 32.7 (25–38.3)
UC 29.6 (25.0–37.0) 35.8 (25–41.1)
Albumin, g/l
CD 29.6 (18.0–37.5) 35.0 (28.1–42.4)
UC 27.9 (25.6–41.0) 40 (36.5–48.0)
C- reactive protein, mg/dl
CD 4.0 (3.0–8.1) 2.6 (1.7–4.56)
UC 1.1 (0.1–3.0) 0.9 (0.1–2.6)
fecal calprotectin, μg/g stool
CD not applicable (n/a) n/a
UC 1482 (84–5910) 187 (5–9750)
Concomitant medication
Corticosteroids   
  CD, n 4/6 4/6
  dosage, milligram per kilogram bodyweight (mg/KG BW) 0.25 (0.1–0.4) 0.23 (0.1–0.4)
  UC, n 4/5 1/5
  dosage, mg/KG BW 1 (0.5–1.5) 0.2
Azathioprine
CD, n 2/6 2/6
UC, n 1/5 1/5
Mesalazine
CD, n 2/6 2/6
UC, n 0/5 1/5